---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269992"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:23:51.124206+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro to acquire IRRAS for $5M cash + 1.325M shares; combined 2026 rev $54-60M

## Summary
- Total consideration: $5M cash plus 1.325M ClearPoint shares; earnout of 25% of net IRRA flow sales above thresholds.
- IRRAS's IRRA flow catheter addresses ~400K US procedures/yr, targeting a $0.5B global intracranial bleeding market.
- IRRAS has >50 active customers and 83% growth in first 9 months of 2025 to ~$9M revenue run-rate.
- Combined entity expected to have 40+ additional commercial professionals; 2026 revenue guidance $54M-$60M.
- Transaction approved by both boards; closing conditions include IRRAS stockholder approval and Nasdaq Stockholm delisting by Dec 31, 2025.

## SEC filing metadata
- accession: 0001193125-25-269992
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000119312525269992/0001193125-25-269992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000119312525269992/clpt-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269992
- JSON: https://secwatch.observer/filing/0001193125-25-269992.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.